 Pancreatic cancer is one of the deadliest cancers and one of its features is that it's a highly chemotherapy resistant and the problem is that cancer cells are surrounded by thick material that we call stroma that prevents access to drugs and drug delivery. The stroma in pancreatic cancer is comprised of stroma cells such as immune cells and fibroblasts. Last year we identified two different types of fibroblasts that might have potentially different roles in promoting tumor progression. We believe that one type of fibroblast is an inflammatory type that promotes tumor growth and creates an immunosuppressive environment and the other type of fibroblasts might have tumor restraining functions. So we recently identified the molecules secreted by cancer cells that activate the fibroblasts to be one or the other and we can now selectively target the signaling pathways within the fibroblasts to shift them from a tumor promoting one to a tumor restraining one. We believe that to achieve an effective therapeutic strategy we will need to target all the tumor promoting components within the stroma and not just cancer cells. So moving forward we are trying to identify the other type of fibroblasts to selectively target them and understand their functions within the tumor.